BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

BNP Paribas Financial Markets lowered its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) by 79.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,622 shares of the biotechnology company’s stock after selling 14,077 shares during the quarter. BNP Paribas Financial Markets’ holdings in Capricor Therapeutics were worth $50,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in Capricor Therapeutics by 51.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 37,868 shares during the period. Swiss National Bank purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $930,000. Alliancebernstein L.P. purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $183,000. The Manufacturers Life Insurance Company lifted its holdings in Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after buying an additional 2,361 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Capricor Therapeutics by 37.8% in the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after buying an additional 241,279 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CAPR shares. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. HC Wainwright restated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. Finally, Roth Capital started coverage on Capricor Therapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $31.00 price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.50.

Capricor Therapeutics Trading Up 9.2%

Shares of NASDAQ:CAPR opened at $11.15 on Wednesday. The stock has a fifty day simple moving average of $10.14 and a two-hundred day simple moving average of $13.03. The stock has a market capitalization of $509.30 million, a price-to-earnings ratio of -10.52 and a beta of 0.85. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The company had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same quarter in the previous year, the firm posted ($0.31) EPS. As a group, equities research analysts predict that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.